Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 51, Issue 1, 1996, Pages 87-90

  Weber, C ^a   Tam, Y K ^b   Schmidtke Schrezenmeier, G ^c   Jonkmann, J H G ^d   Van Brummelen, P ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Gesell F Pharmakologische U   (Germany)

^d PRA International USA   (Netherlands)

Author keywords

Atenolol; Captopril; Furosemide; Healthy volunteers; Nifedipine; Orlistat; Pharmacokinetics

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; CAPTOPRIL; ENZYME INHIBITOR; FUROSEMIDE; NIFEDIPINE; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CALCIUM CHANNEL BLOCKERS; CAPTOPRIL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DIURETICS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; FUROSEMIDE; HUMANS; HYPERTENSION; LACTONES; MALE; NIFEDIPINE;

EID: 0029740253     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050165     Document Type: Article

References (24)

1. Consensus Conference, (1985) Lowering blood cholesterol to prevent heart disease. JAMA 253:2080-2086
2. Garrow JS (1991) Treating obesity Br med J 302:804-804
3. Bray GA (1992) Pathophysiology of obesity. Am J Clin Nutr 55:488S-494S
4. Borgstroem B (1988) Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim Biophys Acta 962:308-316
5. Hadvary P, Lengsfeld H, Wolfer H (1988) Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J 256:357-361
6. Meier MK, Blum-Kaelin D, Bremer K, Isler D, Joly R, Keller-Rupp P, Lengsfeld H (1991) Preclinical profile of the lipase inhibitor tetradydrolipstatin (Ro 18 0647, THL), a potential drug for the treatment of obesity. Int J Obesity 15 [Suppl 1]:31
7. Hogan S, Fleury P, Hadvary P (1987) Studies on the antiobesity activity of tetradydrolipstatin, a potent and selective inhibitor of pancreatic lipase. Int J Obesity 11 [Suppl. 3]:35-42
8. Güzelhan C, Crijns HJMJ, Peeters PAM, Jonkman JHG, Hartmann D (1991) Pharmacological activity (inhibition of fat absorption) and tolerability in healthy volunteers of tetrahydrolipstatin (THL) a specific lipase inhibitor. Int J Obesity 15 [Suppl 1]:29
9. Hauptmann J, Jeunet F, Hartmann D (1992) Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18 0647 (tetrahydrolipstatin). Am J Nutr 55:309S-313S
10. Hartmann D, Hussain Y, Güzelhan C, Odink J (1993) Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake. Br J Clin Pharmacol 36:266-270
11. Pereira CM, Tam YK, Collins-Nakai RL, Ng P (1988) Simplified determination of captopril in plasma by high performance liquid chromatography. J Chromatography 425: 280-213
12. Gibaldi M, Perrier D (1982) Pharmacokinetics. 2nd edn. Marcel Dekker, New York
13. Rupp W (1980) Some aspects of clinical pharmacology of furosemide. Arch Int Pharmacodyn Ther Suppl: 119-129
14. Mason WD, Winer N, Kochak O, Cohen J, Bell R (1979) Kinetics and absolute bioavailability of atenolol. Clin Pharamcol Ther 25:408-415
15. Grahnen A, Hammarlund M, Lundqvist T (1984) Implications of intraindividual variability in bioavailability studies of furosemide. Eur J Clin Pharmacol 27:595-602
16. Kelly MR, Cutler RE, Forrey AW, Kimpel BM (1074) Pharmacokineties of orally administered furosemide. Clin Pharmacol Ther 15:178-186
17. Idle JR, Sever PS (1983) Treatment of angina pectoris with nifedipine Br med J 286:1978-1979
18. Kleinbloesem CH, van Brummelen P, van de Linde JA, Voogd PJ, Breimer DD (1984) Nifedipine: Kinetics and dynamics in healthy subjects. Clin Pharmacol Ther 35:742-749
19. Lobo J, Jack DB, Kendall MJ (1986) The intra- and inter-subject variability of nifedipine pharmacokinetics in young volunteers. Eur J Clin Pharmacol 30:57-60
20. Duchin KL, McKinstrey DN, Cohen AI, Migdalof BH (1988) Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. Clin Pharmacokinetics 14:241-259
21. Kubo SH, Cody RJ (1985) Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors: A review. Clin Pharmacokinetics 10:377-391
22. Duchin KL, Singhvi SM, Willard DA, Migdalof BH, McKinstrey DN (1982) Captopril kinetics. Clin Pharmacol Ther 31:452-458
23. Hartmann D, Güzelhan C, Crijns HJMJ, Peeters PAM, Persson P, Jonkman JHG (1993) Comparison of galenic formulations of orlistat (tetrahydrolipstatin), a pharmacological approach. Drug Invest 5:44-50
24. Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, Patel IH (1994) Retrospective population-based analysis of dose-response (fetal fat excretion) relationship of orlistat in healthy or obese volunteers. Clin Pharmacol Ther 156:82-85